Brief: Imricor’S Visabl-Afl Trial For Us FDA Approval Commences
25/06/2024 12:03
June 25 (Reuters) - Imricor Medical Systems Inc
IMR.AX :
* IMRICOR’S VISABL-AFL TRIAL FOR US FDA APPROVAL COMMENCES
AT
CARDIOVASCULAR INSTITUTE OF SOUTH PARIS
Source text for Eikon: ID:nBwbKlM1a
Further company coverage: IMR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imricor Medical Systems
See all newsBrief: Imricor Medical Systems Says FDA Completes Review Of Imricor's Third PMA Module
Brief: Imricor Medical Systems Says FDA Accepts Imricor Pma Manufacturing Module
Brief: Imricor Medical Systems Says Anticipated FDA Clearances Of Additional Capital Equipment Expected To Broaden Product Offering Available To U.S. Customers
Imricor Medical Systems hits 3-month high on securing first US hospital customer
Brief: Imricor Medical Systems, Receives FDA 510(K) Clearance For Northstar Pediatric Label Expansion